Compare Agnico Eagle Mines Ltd (AEM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

AEM trades at $185.71, up 2.9% over the past day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $11.91 billion in 2025, with a net income margin of 40.44%, and maintains a solid balance sheet with total assets of $29.99 billion. Recent news highlights record free cash flow and a 20-30% gold production growth target through organic expansion.

The stock offers upside to the consensus price target of $219.63, supported by strong profitability and analyst optimism, but faces risks from rising costs and gold price volatility. With 67.74% of analysts rating it a buy, AEM remains a compelling play on gold, though investors should monitor cost pressures and production guidance.

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.